Daré Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the annual meeting of stockholders held on June 21, 2023. Daré Bioscience, Inc. is a Delaware corporation with its principal executive offices in San Diego, CA, and its common stock trades on the Nasdaq Capital Market under the symbol "DARE".
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Three proposals were voted upon by stockholders:
- Proposal 1 (Election of Directors): All Class III director nominees were elected.
- Cheryl R. Blanchard, Ph.D.: 22,509,430 votes for; 3,095,043 votes withheld.
- Sabrina Martucci Johnson: 23,447,732 votes for; 2,156,741 votes withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Mayer Hoffman McCann P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Votes For: 48,270,018
- Votes Against: 1,341,227
- Abstentions: 262,151
- Proposal 3 (Executive Compensation): Stockholders approved, on an advisory basis, the compensation of named executive officers.
- Votes For: 22,399,824
- Votes Against: 3,026,516
- Abstentions: 178,133
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares entitled to vote and the quorum status at the June 21, 2023 meeting.
- Review the definitive proxy statement filed on April 27, 2023, for detailed biographies of the elected directors and the specific compensation metrics approved in Proposal 3.
- Confirm the engagement letter terms with the newly ratified auditor, Mayer Hoffman McCann P.C.